Bioequivalence Study of Amlodipine 10mg Tablets Under Fed Conditions

NCT ID: NCT00775151

Last Updated: 2008-10-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2005-07-31
• Study Completion Date: 2005-11-30

Brief Summary

The objective of this study was to compare the rate and extent of absorption of Ranbaxy amlodipine 10 mg tablet to that of Norvasc® 10 mg tablet after a single, one tablet dose in fed state subjects.

Detailed Description

The study was conducted as an open label, balanced, randomised, two-treatment, two-period, two-sequence, single-dose, crossover , bioequivalence study on Amlodipine besylate formulations comparing Amlodipine 10mg tablets of Ranbaxy Laboratories with (Norvasc®, Pfizer Inc USA, in healthy, adult, human, subjects under fed conditions

Enrolled and randomized: 40 each treatment) Drop-outs (withdrew from study): 1 Withdrawals (was dropped from study): 4 Completed: 36

Conditions

Healthy

Keywords

Bioequivalence amlodipine 10 mg tablet under fed conditions

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

1

amlodipine 10 mg tablet of Ranbaxy

Group Type: EXPERIMENTAL

amlodipine 10 mg tablet

Intervention Type: DRUG

2

Norvasc® 10 mg tablets

Group Type: ACTIVE_COMPARATOR

amlodipine 10 mg tablet

Intervention Type: DRUG

Interventions

amlodipine 10 mg tablet

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Is the individual a healthy, normal adult man and woman who volunteers to participate? ls s/he at least 18 years of age? Is his/her BMI between 19 and 30, inclusive? Is she willing .to avoid pregnancy by abstaining from sexual intercourse with a non-sterile male partner, or by the use one of the following methods: diaphragm + spermicide or condom + spermicide (at least 14 days before dosing), intra- uterine contraceptive device or hormonal contraceptives (at least 4 weeks prior to dosing), or has she been surgically sterile or post-menopausal at least six months prior to entering into the stndy?

• Is s/he considered .reliable and capable of understanding his/her responsibility and role in the study.
• Has s/he provided written informed consent?

A no answer to any of the above questions indicated that the individual was ineligible for enrollment

Exclusion Criteria

• Does the individual have a history of allergy or hypersensitivity to amlodipine? Does s/he have clinically significant laboratory abnormalities that would interfere with the conduct or interpretation of the study or jeopardize his/her safety?
• Does s/he have significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hematopoietic, hepatic, neurological, ongoing infection, pancreatic, or renal diseases that would interfere with the conduct or interpretation of the study or jeopardize his/her safety'?
• Is she nursing?
• Does s/he have serious psychological illness?
• Does s/he have significant h/story (within the past year) or clinical evidence of alcohol or drug abuse? •
• Does s/he have a positive urine drug screen or a positive HIV-1, or hepatitis B or C screen, or a positive pregnancy test? Has s/he consumed grapefruit or grapefruit juice during the 7rday period preceding study initiation?
• Is s/he unable to refrain from the use of alcohol or xanthine-containing foods or beverages during periods beginning 48 hours prior to study drug administration and ending when the last blood sample has been taken in each study period?
• Has s/he used any prescription drug, other than hormonal contraceptives, during the 14-day period prior to study initiation, or any OTC drug during the 72-hour period preceding study initiation?
• Is s/he unable to refrain from the use of all concomitant medications, other than hormonal contraceptives, during the study?
• Has s/he donated or lost blood, or participated in a clinical study which involved the withdrawal of a large volume of blood (480 mL or more), during the six week period preceding study initiation?

Has s/he donated plasma during the two week period preceding study initiation? Has s/he received an investigational drug during the 30 day period preceding study initiation? Is s/he a heavy smoker (usually smoking more than 10 cigarettes per day)?

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ranbaxy Laboratories Limited

INDUSTRY

Sponsor Role: lead

Responsible Party

Ranbaxy Research Labs

Locations

SFBC Ft. Myers, Inc.

Fort Myers, Florida, United States

Countries

United States

Related Links

http://clinicalstudies.ranbaxy.com

Related Info

http://www.fda.gov/opacom/7alerts.html

Related Info

http://dailymed.nlm.nih.gov/dailymed/about.cfm

Related Info

Other Identifiers

50366

Identifier Type: -

Identifier Source: org_study_id